William Collier

Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.

Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.

Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018.

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom.

Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC.

Genevant Sciences, Inc. is a company based in Cambridge, MA that specializes in nucleic acid drug development and delivery. The company has developed lipid nanoparticle (LNP) technology and next-generation ligand conjugate technology for delivery of gene editing payloads, small interfering RNA (siRNA), and other oligonucleotide payloads. The company has a robust and expansive LNP patent estate and decades of experience and expertise in nucleic acid drug development. The company is committed to maximizing every opportunity to transform the future of human health by expanding their focus to extrahepatic tissues and cell types, such as the lung, stellate cells, and leukocytes. Genevant Sciences has built expertise in siRNA payload design and development and has more than 700 patents worldwide that they own or license. The company is open, collaborative, and entrepreneurial, and are always ready to connect with people interested in the pioneering work they do.

Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Unilife Medical Solutions, Inc. operates as a medical device contract manufacturer of disposable devices. It engages in the design, development, and validation of automated equipment used in the production of medical devices. The firm’s project management services include product design and support and prototyping, molding, assembly, printing, packaging, sterilization, and quality control. The company is headquartered in York, PA.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Part of Blank Rome LLP, Dyer Ellis & Joseph is a legal services provider. The company is based in Washington. Dyer Ellis & Joseph was acquired by Blank Rome Comisky & McCauley LLP on January 07, 2003.

The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay.

Tufts Associated Health Plans, Inc. provides healthcare plans. It offers health care coverage options to individuals and employer groups. The firm also offers choice tiered network option plan and Steward Community Choice, a community-based plan, developed in conjunction with Steward Health Care System. The company was founded by Morton A. Madoff in 1979 and is headquartered in Watertown, MA.

Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million.

Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Boys & Girls Clubs of Metro Los Angeles is a non-profit organization that was founded in December 2015 to provide a sustainable solution to the opportunity crises facing vulnerable children in the neediest neighborhoods of Los Angeles. Boys & Girls Clubs of Metro Los Angeles is based in Los Angeles, CA, and has subsidiaries in the United States. The organization operates four clubs in Bell Gardens, Challengers, Downs, and Willowbrook, and offers nationally recognized, research-based programs and activities in three core areas: academic success, good character and citizenship, and healthy lifestyles. The organization empowers youth to explore a future with endless possibilities by offering creative programming, such as new approaches to science, technology, engineering, and math (STEM) created in collaboration with community partners. The non-profit company was founded in 2015, and the CEO is Patrick Mahoney.

Koch Industries, Inc. engages in the manufacture and trade of chemical products. It operates in variety of industries such as polymers and fibers, fertilizers, electronics, automotive components, forest and consumer products, minerals, glass, process and pollution control systems, refining and biofuels, commodity trading, investments, and ranching. The company was founded by Frederick Chase Koch in 1940 and is headquartered in Wichita, KS.

Blank Rome LLP provides legal services. The firm's services include commercial litigation, labor and employment benefits, bankruptcy, energy, financial services, health care, shareholder activism, tax and many more. The company was founded in 1946 and is headquartered in Philadelphia, PA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Orrick, Herrington & Sutcliffe LLP engages in the provision of legal services. Its practices include: antitrust and competition; banking and finance; capital markets; copyright, trademark and false advertising; cyber, privacy and data innovation; employment law and litigation; energy; financial services litigation; global compliance and regulatory, infrastructure; intellectual property; patents; public finance; real estate; securities litigation; supreme court and appellate; tax advocacy; technology transactions; trials; and white collar, investigations, securities litigation and compliance. The company was founded by John R. Garboe in 1863 and is headquartered in San Francisco, CA.

Cedars-Sinai Medical Center operates a hospital that provides healthcare services. It specializes in cancer, endocrinology, gynecology, neurology, orthopedics, and respiratory disorders. The company was founded in 1902 and is headquartered in Los Angeles, CA.

LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer.